India’s primary market gears up for another action-packed week with 10 IPOs set to launch and three listings scheduled. Among the highlights, refurbished electronics giant GNG Electronics is opening its IPO on July 23 to raise approximately ₹460 crore, primarily to reduce debt and support general business expansion.

India’s capital markets are set for heightened activity next week with 10 IPOs expected to launch and three companies, including Anthem Biosciences, scheduled to list. Among the key issuers is GNG Electronics, India’s leading refurbisher of laptops, desktops, and ICT devices, which is gearing up for its mainboard IPO launch on July 23.

The company has set a price band of ₹225–237 per equity share. The public issue includes a fresh issue worth ₹400 crore and an offer-for-sale (OFS) of 25.5 lakh shares, bringing the total issue size to approximately ₹460.44 crore at the upper price band. The IPO will close on July 25, with allotment scheduled by July 28. Shares are expected to be listed on both the BSE and NSE by July 30.

The proceeds from the IPO will primarily be used to reduce GNG Electronics’ debt burden by ₹320 crore, with the remainder allocated toward general corporate purposes. This aligns with the company’s strategic plan to strengthen its balance sheet and fund growth in domestic and international refurbishing operations.

GNG Electronics operates five refurbishing facilities across India, the USA, and the UAE. With operations spanning India, Europe, Africa, and the Middle East, the company commands a strong position in the global refurbished electronics market. Its competitive edge lies in scale, operational efficiency, and expanding global presence.

Despite facing minimal competition from publicly listed peers, GNG’s IPO aims to capitalize on investor interest in tech-enabled circular economy models. The company is looking to differentiate itself by enhancing technology, scaling refurbishing processes, and capturing growing demand for affordable electronics across developing and developed markets.

GNG Electronics has shown robust financial performance in recent years, with revenue in FY24 reaching ₹1,138.1 crore and profits at ₹52.3 crore. The company has projected continued growth in FY25, reflecting its operational momentum and the growing demand for sustainable electronics solutions.

This IPO is expected to attract institutional and retail interest, given the company’s strong fundamentals, wide geographic footprint, and focus on debt reduction—an essential step in unlocking higher margins and long-term investor value.

Read the full article here: GNG Electronics Powers Into Markets With ₹460 Cr IPO — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

India-based Anthem Biosciences is set to finalize its IPO allotment today, July 17, 2025, following robust investor demand. With a ₹3,395 crore offer entirely via offer-for-sale, the IPO saw an overall subscription of 63.86 times. The company’s shares are trading at a ₹144 premium in the grey market, indicating a potential 25.26% listing gain.

India’s pharmaceutical research and development leader Anthem Biosciences is under investor spotlight today, July 17, as it finalizes share allotment for its highly subscribed initial public offering (IPO). The public issue, launched on July 14 and closed on July 16, attracted significant investor interest, signaling continued enthusiasm for the pharmaceutical sector.

The ₹3,395 crore IPO was entirely an offer-for-sale of 5.96 crore equity shares, priced at ₹570 apiece. The company will not receive any fresh capital from this issue, with the offering designed to provide an exit to existing shareholders.

Strong Subscription Across Investor Categories

The IPO was subscribed a remarkable 63.86 times overall. Among key investor segments, Qualified Institutional Buyers (QIBs) led with 182.65 times subscription, followed by Non-Institutional Investors (NIIs) at 42.36 times. The retail investor portion saw 5.64 times oversubscription, reflecting widespread participation.

This overwhelming demand indicates institutional confidence in Anthem Biosciences’ R&D-driven business model, which is focused on contract research and manufacturing for global biopharmaceutical clients. Analysts attribute the response to the company’s robust financials and strong future revenue visibility in the rapidly expanding global life sciences market.

GMP Signals Bullish Sentiment

The grey market premium (GMP) for Anthem Biosciences shares stood at ₹144 today, pushing the estimated listing price to ₹714. This suggests a potential 25.26% premium over the IPO issue price. While grey market trends are unofficial, they are often viewed as a directional indicator of listing expectations.

The equity shares are scheduled to be credited to demat accounts on July 18, with refunds initiated for unsuccessful bidders on the same day. The listing is expected on July 21 on both BSE and NSE.

How to Check Anthem Biosciences IPO Allotment Status

Investors can check their IPO allotment status online through the websites of the stock exchanges and the IPO registrar Kfin Technologies. Here are the methods:

On BSE:

1. Go to BSE IPO Allotment Page
   
2. Select ‘Equity’ and choose ‘Anthem Biosciences Limited’
   
3. Enter PAN or Application Number
   
4. Complete the captcha and click ‘Search’
   

On NSE:

1. Visit NSE Allotment Status Page
   
2. Choose ‘Equity and SME IPO bids’ and select the IPO
   
3. Enter PAN and Application Number, then submit
   

On Kfin Technologies:

1. Access Kfin IPO Allotment Portal
   
2. Select ‘Anthem Biosciences Limited’
   
3. Enter either PAN, Application Number, or Demat details
   
4. Submit the Captcha and check status
   

Market Implications

The strong debut anticipated for Anthem Biosciences mirrors a broader bullish trend in India’s primary market. High oversubscription levels, especially from QIBs, often suggest strong institutional endorsement and long-term conviction. If listing gains materialize, it could bolster sentiment for upcoming IPOs in the pharmaceutical and biotechnology space.

The successful listing of Anthem Biosciences could further validate the increasing role of India in global life sciences R&D outsourcing, a space expected to expand significantly in the next decade. Investors now await the final listing with a keen eye on market conditions and post-listing performance.

Read the full article here: Anthem Biosciences IPO Allotment Today: How to Check Status Online — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

India-based Anthem Biosciences, a Bengaluru-headquartered CRDMO, is set to close its ₹3,395 crore IPO on July 16. With a grey market premium suggesting nearly 27% listing gains and an overall subscription of 3.48x so far, investor interest remains strong. However, subdued QIB participation and the IPO’s Offer for Sale (OFS) structure are key factors influencing institutional sentiment.

The ₹3,395 crore Initial Public Offering (IPO) of Anthem Biosciences, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is set to close today. Headquartered in Bengaluru, Anthem Biosciences provides end-to-end services across new chemical and biological entity development, positioning itself as a key player among Indian life sciences firms.

The IPO, which opened on July 14, is structured entirely as an Offer for Sale (OFS) of 5.96 crore equity shares by the company’s promoters and early investors. As no fresh equity is being issued, the company will not receive any capital from the IPO proceeds—an aspect often viewed conservatively by long-term institutional investors.

GMP Signals Optimism but Institutional Sentiment Remains Cautious

As of July 16, Anthem Biosciences’ shares are trading at a grey market premium (GMP) of approximately ₹156–₹160 per share over its upper price band of ₹570. This indicates an estimated listing price of ₹726, implying a speculative gain of about 27%, though GMP is not an official indicator and can shift rapidly with market sentiment.

While retail and high-net-worth individuals have responded positively, institutional participation remains muted. Subscription data as of today shows an overall bid coverage of 3.48x, with Non-Institutional Investors (NIIs) subscribing 10.26x, and Retail Investors covering 2.21x. However, Qualified Institutional Buyers (QIBs) trail behind at only 0.62x, raising questions about institutional confidence in the short-term growth narrative.

Key Dates: Allotment and Listing Timeline

• IPO Closes: July 16, 2025
  
• Allotment Finalization: Expected by July 17, 2025
  
• Listing Date: Tentatively July 21, 2025, on BSE and NSE
  

The IPO is managed by JM Financial as the book-running lead manager, with Kfin Technologies serving as the official registrar.

What Sets Anthem Apart

Founded in 2006, Anthem Biosciences has carved a niche in the CRDMO segment by integrating drug discovery with development and commercial-scale production. With dual expertise in New Chemical Entities (NCE) and New Biological Entities (NBE), the company operates with a cross-disciplinary team of chemists, engineers, and biologists, serving clients across the pharmaceutical value chain.

The firm’s focus on capitalizing on India’s competitive cost structure for outsourced pharma R&D and manufacturing has contributed to its rising relevance among global biotech players seeking reliable partners.

Market Sentiment and Long-Term View

While the initial investor enthusiasm—reflected in the GMP and oversubscription among NIIs—underscores market optimism, the OFS structure, coupled with subdued QIB participation, suggests a more nuanced institutional stance. Investors are likely watching for post-listing disclosures on growth trajectory, capacity expansions, and client acquisition to gauge long-term value.

With India’s CRDMO sector projected to grow at over 12% CAGR through 2030, firms like Anthem Biosciences are well-positioned to benefit. However, valuation metrics post-listing will determine whether the current enthusiasm translates into sustained performance on the bourses.

Read the full article here: Anthem Biosciences IPO Ends Today: 27% GMP—Worth the Bet? — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

Anthem Biosciences’ ₹3,395 crore IPO has been fully subscribed by July 15, 2025, driven by strong demand from Non-Institutional Investors and Retail Investors. The Bengaluru-based biotech company focuses on innovation-led contract research, development, and manufacturing services and is set to list its shares on July 21, 2025.

Bengaluru-based Anthem Biosciences Ltd, a leading Contract Research, Development and Manufacturing Organization (CRDMO), achieved full subscription for its Initial Public Offering (IPO) by July 15, 2025. The ₹3,395 crore issue was subscribed 1.15 times by the second day of bidding, according to data from the National Stock Exchange (NSE).

Anthem Biosciences operates in the biotech space with innovation-driven, technology-focused solutions across drug discovery, development, and manufacturing. It also produces advanced fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.

The IPO has attracted notable attention from Non-Institutional Investors (NIIs), who subscribed 2.82 times their allotted quota. The Retail Individual Investors (RIIs) followed closely with an 89% subscription, while Qualified Institutional Buyers (QIBs) showed 38% subscription levels as of 11:00 a.m. on July 15.

The offering includes a price band of ₹540–₹570 per share and is set to close on July 16, 2025. Prior to the public bidding, Anthem Biosciences raised ₹1,016 crore from anchor investors.

Market analysts tracking grey market activities have reported a Grey Market Premium (GMP) of ₹116, indicating a 20.35% potential listing gain. The shares are scheduled to be listed on the NSE and BSE on July 21, with the allotment finalization expected by July 17.

Investors are closely watching the listing performance, especially amid growing interest in the Indian biotech and pharmaceutical manufacturing space.

Read the full article here: Anthem Biosciences Joins the IPO Elite with Massive Backing — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

India-based Anthem Biosciences Limited, a leading CRDMO company, launched its ₹3,395 crore IPO on July 14, 2025. The offer, open till July 16, saw early subscription interest despite being a complete offer-for-sale. With a grey market premium of ₹101 and strong financials, experts are recommending a “Subscribe” rating.

Anthem Biosciences Limited, one of India’s leading Contract Research, Development, and Manufacturing Organizations (CRDMOs), opened its Initial Public Offering (IPO) for subscription on July 14, 2025. Headquartered in Bengaluru, Karnataka, Anthem Biosciences provides fully integrated services across drug discovery, development, and manufacturing with capabilities in both New Chemical Entities (NCEs) and New Biological Entities (NBEs).

The IPO will remain open till July 16, 2025, and aims to raise ₹3,395 crore entirely through an Offer for Sale (OFS). The company has set the price band between ₹540 and ₹570 per equity share, with a lot size of 26 shares. Anthem Biosciences shares are proposed to be listed on both BSE and NSE.

As of 12:21 PM on day one of the issue, the IPO was subscribed 0.21 times overall. The retail individual investor (RII) portion was subscribed 0.24 times, while the Non-Institutional Investor (NII) portion saw a 0.42 times subscription.

Market observers report a Grey Market Premium (GMP) of ₹101 today, indicating positive investor sentiment. The most likely date for share allotment is July 17, 2025, and listing is expected on July 21, 2025.

The company’s financials reflect robust performance. For the year ending March 2025, Anthem Biosciences posted a revenue of ₹1,844.55 crore and a Profit After Tax (PAT) of ₹451 crore, yielding a healthy net margin of 23.4%. Its earnings per share (EPS) is ₹8.04, with a PE ratio in the range of 67.16 to 70.90 on a fully diluted basis.

Importantly, the promoter-founder is not selling any shares in this OFS and will retain over 52% post-issue stake, which analysts see as a positive sign for long-term investors.

JM Financial, Citigroup Global Markets, JP Morgan India, and Nomura Financial Advisory are the lead managers for the issue, and KFin Technologies Ltd is the registrar.

Read the full article here: Anthem IPO Opens: Should You Trust the ₹101 Grey Premium? — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

Anthem Biosciences, a Karnataka-based innovation-led CRDMO, has announced its IPO price band of ₹540–₹570 per share. The ₹3,395 crore public issue will open on July 14, 2025, and close on July 16. The issue is a complete offer for sale with shares set to list on both NSE and BSE.

Anthem Biosciences Ltd, a leading innovation-driven Contract Research, Development, and Manufacturing Organization (CRDMO), headquartered in Karnataka, India, has announced the launch of its ₹3,395 crore Initial Public Offering (IPO). The IPO will open for public subscription from July 14 to July 16, 2025, with the anchor book opening on July 11, 2025.

The price band for the IPO has been fixed at ₹540 to ₹570 per share, with a face value of ₹2 each. The public issue is entirely an Offer for Sale (OFS) of 5.96 crore equity shares by existing shareholders. Therefore, the company will not receive any direct proceeds from the offering.

The IPO will be listed on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE), with a tentative listing date of July 21, 2025. Post-closure, allotment is expected to be finalized on July 17, with refunds and share credits processed by July 18.

The offering is structured with 50% reserved for Qualified Institutional Buyers (QIBs), 15% for Non-Institutional Investors (NIIs), and 35% for Retail Investors. An additional ₹8.25 crore worth of equity shares have been reserved for eligible employees. Retail investors can apply in lots of 26 shares, requiring a minimum investment of ₹14,820.

Anthem Biosciences specializes in fermentation-based Active Pharmaceutical Ingredients (APIs) including enzymes, peptides, probiotics, biosimilars, and nutritional actives. The company operates two integrated manufacturing facilities in Karnataka — Unit I in Bommassandra and Unit II in Harohalli — with a combined annual capacity of 270 kL for custom synthesis and 142 kL for fermentation.

Among its industry peers are Sai Life Sciences, Syngene International, Suven Life Sciences, and Divi’s Laboratories.

The IPO is being managed by JM Financial Ltd, Citigroup Global Markets India, J P Morgan India, and Nomura Financial Advisory & Securities (India), while KFin Technologies is the registrar for the issue.

This IPO underscores investor interest in India’s growing pharmaceutical manufacturing and research sector, especially in the CRDMO segment.

Read the full article here: A Pharmaceutical Giant’s Secret Bet on India’s Stock Market — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

India’s IPO landscape is witnessing a slowdown as global economic concerns and geopolitical tensions take center stage. On May 6, 2025, it was reported that several Indian firms, including Avanse Financial and Anthem Biosciences, have put their IPO plans on hold due to weak investor sentiment and market instability. The upcoming IPO of Ather Energy will likely serve as a gauge for investor confidence in these uncertain times.

India’s initial public offering (IPO) market is experiencing a notable deceleration as companies postpone their listing plans in response to global economic jitters and subdued investor interest. Among the firms delaying IPOs are Mumbai-based Avanse Financial, a non-banking financial company focused on education loans, and Anthem Biosciences, a Bengaluru-based biopharmaceutical research and manufacturing firm.

At least two IPOs valued at approximately USD 759 million are expected to be pushed back. Investment bankers attribute this trend to weakening investment sentiment driven by global economic uncertainty and persistent geopolitical tensions, including ongoing friction between India and Pakistan.

The broader environment—marked by global trade disruptions, inflationary concerns, and recession fears—has already led nearly 58 Indian companies with regulatory clearance to postpone their IPOs. Many of these approvals, granted by the Securities and Exchange Board of India (SEBI), are nearing expiration, creating pressure for companies to act swiftly or refile applications.

A key IPO that investors are closely monitoring is that of Ather Energy, an Indian electric vehicle company based in Bengaluru. Its public listing is being viewed as a critical barometer of investor appetite amid uncertain market conditions.

Adding to the complexity, regulatory delays and unstable capital flows are pushing firms to reassess fundraising strategies. As market confidence teeters, India’s capital market momentum is at risk of losing ground. The performance of upcoming IPOs may determine whether companies proceed or continue to sit on the sidelines.

Read the full article here: The Great IPO Slowdown: India Waits While the US Wobbles — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).